(EBS) Emergent Biosolutions - Overview
Stock: Vaccines, Antitoxins, Autoinjectors, Manufacturing
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 122% |
| Relative Tail Risk | -24.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.43 |
| Alpha | -21.64 |
| Character TTM | |
|---|---|
| Beta | 1.551 |
| Beta Downside | 1.589 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.79% |
| CAGR/Max DD | -0.06 |
Description: EBS Emergent Biosolutions December 29, 2025
Emergent BioSolutions (NYSE:EBS) is a U.S. life-sciences firm that focuses on medical countermeasures for public-health threats, offering a portfolio that spans emergency opioid overdose treatment (NARCAN), vaccines against cholera, typhoid, anthrax, smallpox, and botulism, as well as therapeutics for Ebola, Lassa fever, and other high-consequence pathogens. The company also provides contract development and manufacturing services (CDMO) for drug substance, product, and packaging, leveraging its expertise in biologics and sterile manufacturing.
Key operating metrics that shape its outlook include FY 2023 total revenue of roughly $1.1 billion, with about 70 % derived from U.S. government contracts-a concentration that makes federal biodefense spending a primary driver of earnings. R&D spend averaged $200 million in the same year, supporting a pipeline of more than a dozen late-stage candidates, including EBS-LASV (Lassa fever) and EBS-MARV (Marburg). The broader biotechnology sector is benefiting from a projected 8 % CAGR in global biodefense funding through 2028, reflecting heightened geopolitical risk and pandemic preparedness initiatives.
For a deeper quantitative view, you might explore ValueRay’s analyst platform to see how these factors are reflected in the stock’s valuation.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 75.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -9.25 > 1.0 |
| NWC/Revenue: 82.44% < 20% (prev 38.34%; Δ 44.11% < -1%) |
| CFO/TA 0.01 > 3% & CFO 13.0m > Net Income 75.9m |
| Net Debt (417.6m) to EBITDA (215.9m): 1.93 < 3 |
| Current Ratio: 5.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.5m) vs 12m ago 1.62% < -2% |
| Gross Margin: 57.80% > 18% (prev 0.36%; Δ 5744 % > 0.5%) |
| Asset Turnover: 53.69% > 50% (prev 76.16%; Δ -22.47% > 0%) |
| Interest Coverage Ratio: 2.01 > 6 (EBITDA TTM 215.9m / Interest Expense TTM 59.4m) |
Altman Z'' 3.10
| A: 0.45 (Total Current Assets 786.9m - Total Current Liabilities 136.5m) / Total Assets 1.46b |
| B: -0.07 (Retained Earnings -105.2m / Total Assets 1.46b) |
| C: 0.08 (EBIT TTM 119.4m / Avg Total Assets 1.47b) |
| D: -0.13 (Book Value of Equity -112.6m / Total Liabilities 878.5m) |
| Altman-Z'' Score: 3.10 = A |
Beneish M -2.97
| DSRI: 1.76 (Receivables 149.5m/121.3m, Revenue 788.9m/1.13b) |
| GMI: 0.63 (GM 57.80% / 36.31%) |
| AQI: 0.89 (AQ_t 0.32 / AQ_t-1 0.36) |
| SGI: 0.70 (Revenue 788.9m / 1.13b) |
| TATA: 0.04 (NI 75.9m - CFO 13.0m) / TA 1.46b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of EBS shares?
Over the past week, the price has changed by -6.75%, over one month by -18.26%, over three months by -0.64% and over the past year by +8.01%.
Is EBS a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the EBS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.5 | 23.6% |
| Analysts Target Price | 13.5 | 23.6% |
| ValueRay Target Price | 10.7 | -1.9% |
EBS Fundamental Data Overview February 04, 2026
P/E Forward = 2.9603
P/S = 0.7919
P/B = 1.0729
P/EG = 1.55
Revenue TTM = 788.9m USD
EBIT TTM = 119.4m USD
EBITDA TTM = 215.9m USD
Long Term Debt = 663.1m USD (from longTermDebt, last quarter)
Short Term Debt = 2.70m USD (from shortTermDebt, last fiscal year)
Debt = 663.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 417.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.04b USD (624.7m + Debt 663.1m - CCE 245.5m)
Interest Coverage Ratio = 2.01 (Ebit TTM 119.4m / Interest Expense TTM 59.4m)
EV/FCF = 744.5x (Enterprise Value 1.04b / FCF TTM 1.40m)
FCF Yield = 0.13% (FCF TTM 1.40m / Enterprise Value 1.04b)
FCF Margin = 0.18% (FCF TTM 1.40m / Revenue TTM 788.9m)
Net Margin = 9.62% (Net Income TTM 75.9m / Revenue TTM 788.9m)
Gross Margin = 57.80% ((Revenue TTM 788.9m - Cost of Revenue TTM 332.9m) / Revenue TTM)
Gross Margin QoQ = 60.32% (prev 43.08%)
Tobins Q-Ratio = 0.71 (Enterprise Value 1.04b / Total Assets 1.46b)
Interest Expense / Debt = 2.29% (Interest Expense 15.2m / Debt 663.1m)
Taxrate = 11.11% (6.40m / 57.6m)
NOPAT = 106.1m (EBIT 119.4m * (1 - 11.11%))
Current Ratio = 5.76 (Total Current Assets 786.9m / Total Current Liabilities 136.5m)
Debt / Equity = 1.14 (Debt 663.1m / totalStockholderEquity, last quarter 582.5m)
Debt / EBITDA = 1.93 (Net Debt 417.6m / EBITDA 215.9m)
Debt / FCF = 298.3 (Net Debt 417.6m / FCF TTM 1.40m)
Total Stockholder Equity = 538.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.17% (Net Income 75.9m / Total Assets 1.46b)
RoE = 14.09% (Net Income TTM 75.9m / Total Stockholder Equity 538.5m)
RoCE = 9.94% (EBIT 119.4m / Capital Employed (Equity 538.5m + L.T.Debt 663.1m))
RoIC = 8.82% (NOPAT 106.1m / Invested Capital 1.20b)
WACC = 6.69% (E(624.7m)/V(1.29b) * Re(11.63%) + D(663.1m)/V(1.29b) * Rd(2.29%) * (1-Tc(0.11)))
Discount Rate = 11.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.34%
[DCF Debug] Terminal Value 76.60% ; FCFF base≈56.1m ; Y1≈36.8m ; Y5≈16.8m
Fair Price DCF = 0.25 (EV 430.6m - Net Debt 417.6m = Equity 13.0m / Shares 52.5m; r=6.69% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 47.72 | EPS CAGR: -1.43% | SUE: -0.44 | # QB: 0
Revenue Correlation: -55.82 | Revenue CAGR: -26.23% | SUE: 0.65 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.97 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=4.02 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+148.9% | Growth Revenue=+42.7%